Comprehensive Stock Comparison
Compare Apellis Pharmaceuticals, Inc. (APLS) vs TG Therapeutics, Inc. (TGTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | TGTX | 40.8% revenue growth vs APLS's -11.8% |
| Value | TGTX | Lower P/E (19.4x vs 116.4x) |
| Quality / Margins | TGTX | 13.3% net margin vs APLS's 3.2% |
| Stability / Safety | TGTX | Beta 0.43 vs APLS's 0.84 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | TGTX | 0.0% vs APLS's -16.7% |
| Efficiency (ROA) | TGTX | 8.6% ROA vs APLS's 2.3%, ROIC 13.3% vs 27.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company developing and commercializing therapies that target the complement system — a part of the immune system — for autoimmune and inflammatory diseases. It generates revenue primarily from sales of its approved drug EMPAVELI® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria, with additional revenue from SYFOVRE® (pegcetacoplan injection) for geographic atrophy, and is advancing a pipeline of complement-targeting candidates. Its key advantage is its deep expertise in complement inhibition — a complex biological pathway — and its first-mover position with the first approved therapy for geographic atrophy.
TG Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. It generates revenue primarily from sales of its FDA-approved multiple sclerosis drug BRIUMVI (ublituximab) — its first commercial product — with future revenue expected from its pipeline of oncology candidates. The company's competitive advantage lies in its glycoengineered antibody platform technology, which creates potentially more effective and convenient treatments for complex diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
TGTX leads in 2 of 6 categories (Financial Metrics, Total Returns). APLS leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Financial Metrics (TTM)
APLS is the larger business by revenue, generating $689M annually — 1.5x TGTX's $454M. TGTX is the more profitable business, keeping 13.3% of every revenue dollar as net income compared to APLS's 3.2%. On growth, TGTX holds the edge at +92.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | APLSApellis Pharmaceu… | TGTXTG Therapeutics, … |
|---|---|---|
| RevenueTrailing 12 months | $689M | $454M |
| EBITDAEarnings before interest/tax | $55M | $86M |
| Net IncomeAfter-tax profit | $0 | $60M |
| Free Cash FlowCash after capex | $45M | -$59M |
| Gross MarginGross profit ÷ Revenue | +85.2% | +87.0% |
| Operating MarginEBIT ÷ Revenue | +8.0% | +18.9% |
| Net MarginNet income ÷ Revenue | +3.2% | +13.3% |
| FCF MarginFCF ÷ Revenue | +6.6% | -13.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -153.9% | +92.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -124.1% | +2.9% |
Valuation Metrics
At 116.4x trailing earnings, APLS trades at a 42% valuation discount to TGTX's 200.6x P/E. On an enterprise value basis, APLS's 33.6x EV/EBITDA is more attractive than TGTX's 114.4x.
| Metric | APLSApellis Pharmaceu… | TGTXTG Therapeutics, … |
|---|---|---|
| Market CapShares × price | $2.7B | $4.8B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | 116.44x | 200.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 33.61x | 114.40x |
| Price / SalesMarket cap ÷ Revenue | 3.85x | 14.45x |
| Price / BookPrice ÷ Book value/share | 7.14x | 21.70x |
| Price / FCFMarket cap ÷ FCF | 58.55x | — |
Profitability & Efficiency
TGTX delivers a 21.9% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $7 for APLS. APLS carries lower financial leverage with a 0.30x debt-to-equity ratio, signaling a more conservative balance sheet compared to TGTX's 1.14x. On the Piotroski fundamental quality scale (0–9), APLS scores 6/9 vs TGTX's 3/9, reflecting solid financial health.
| Metric | APLSApellis Pharmaceu… | TGTXTG Therapeutics, … |
|---|---|---|
| ROE (TTM)Return on equity | +7.5% | +21.9% |
| ROA (TTM)Return on assets | +2.3% | +8.6% |
| ROICReturn on invested capital | +27.4% | +13.3% |
| ROCEReturn on capital employed | +7.6% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 3 |
| Debt / EquityFinancial leverage | 0.30x | 1.14x |
| Net DebtTotal debt minus cash | -$354M | $74M |
| Cash & Equiv.Liquid assets | $466M | $180M |
| Total DebtShort + long-term debt | $113M | $254M |
| Interest CoverageEBIT ÷ Interest expense | 1.22x | 3.11x |
Total Returns (with DRIP)
A $10,000 investment in TGTX five years ago would be worth $6,687 today (with dividends reinvested), compared to $4,396 for APLS. Over the past 12 months, TGTX leads with a 0.0% total return vs APLS's -16.7%. The 3-year compound annual growth rate (CAGR) favors TGTX at 23.4% vs APLS's -31.6% — a key indicator of consistent wealth creation.
| Metric | APLSApellis Pharmaceu… | TGTXTG Therapeutics, … |
|---|---|---|
| YTD ReturnYear-to-date | -18.9% | +2.8% |
| 1-Year ReturnPast 12 months | -16.7% | 0.0% |
| 3-Year ReturnCumulative with dividends | -68.0% | +87.8% |
| 5-Year ReturnCumulative with dividends | -56.0% | -33.1% |
| 10-Year ReturnCumulative with dividends | +49.4% | +261.2% |
| CAGR (3Y)Annualised 3-year return | -31.6% | +23.4% |
Risk & Volatility
TGTX is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than APLS's 0.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APLS currently trades 68.8% from its 52-week high vs TGTX's 64.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | APLSApellis Pharmaceu… | TGTXTG Therapeutics, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.84x | 0.43x |
| 52-Week HighHighest price in past year | $30.48 | $46.48 |
| 52-Week LowLowest price in past year | $16.10 | $25.28 |
| % of 52W HighCurrent price vs 52-week peak | +68.8% | +64.7% |
| RSI (14)Momentum oscillator 0–100 | 43.8 | 58.1 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 1.7M |
Analyst Outlook
Wall Street rates APLS as "Buy" and TGTX as "Buy". Consensus price targets imply 64.5% upside for TGTX (target: $50) vs 59.8% for APLS (target: $34).
| Metric | APLSApellis Pharmaceu… | TGTXTG Therapeutics, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.50 | $49.50 |
| # AnalystsCovering analysts | 25 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Apellis Pharmaceuti… (APLS) | 100 | 62.27 | -37.7% |
| TG Therapeutics, In… (TGTX) | 100 | 208.43 | +108.4% |
TG Therapeutics, In… (TGTX) returned -33% over 5 years vs Apellis Pharmaceuti… (APLS)'s -56%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Apellis Pharmaceuti… (APLS) | $0.00 | $689M | — |
| TG Therapeutics, In… (TGTX) | $152381.00 | $329M | +215808.8% |
Apellis Pharmaceuticals, Inc.'s revenue grew from $0M (2016) to $689M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Apellis Pharmaceuti… (APLS) | -137.6% | 3.2% | +102.4% |
| TG Therapeutics, In… (TGTX) | -513.5% | 7.1% | +101.4% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Apellis Pharmaceuti… (APLS) | -1.5 | 0.18 | +112.0% |
| TG Therapeutics, In… (TGTX) | -1.6 | 0.15 | +109.4% |
Apellis Pharmaceuticals, Inc.'s EPS grew from $-1.50 (2016) to $0.18 (2025).
Chart 5Free Cash Flow — 5 Years
Apellis Pharmaceuticals, Inc. generated $45M FCF in 2025 (+108% vs 2021). TG Therapeutics, Inc. generated $-41M FCF in 2024 (+86% vs 2021).
APLS vs TGTX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is APLS or TGTX a better buy right now?
Apellis Pharmaceuticals, Inc. (APLS) offers the better valuation at 116.4x trailing P/E, making it the more compelling value choice. Analysts rate Apellis Pharmaceuticals, Inc. (APLS) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — APLS or TGTX?
On trailing P/E, Apellis Pharmaceuticals, Inc. (APLS) is the cheapest at 116.4x versus TG Therapeutics, Inc. at 200.6x.
03Which is the better long-term investment — APLS or TGTX?
Over the past 5 years, TG Therapeutics, Inc. (TGTX) delivered a total return of -33.1%, compared to -56.0% for Apellis Pharmaceuticals, Inc. (APLS). A $10,000 investment in TGTX five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: TGTX returned +261.2% versus APLS's +49.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — APLS or TGTX?
By beta (market sensitivity over 5 years), TG Therapeutics, Inc. (TGTX) is the lower-risk stock at 0.43β versus Apellis Pharmaceuticals, Inc.'s 0.84β — meaning APLS is approximately 93% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Apellis Pharmaceuticals, Inc. (APLS) carries a lower debt/equity ratio of 30% versus 114% for TG Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — APLS or TGTX?
TG Therapeutics, Inc. (TGTX) is the more profitable company, earning 7.1% net margin versus 3.2% for Apellis Pharmaceuticals, Inc. — meaning it keeps 7.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 12.7% versus 8.0% for APLS. At the gross margin level — before operating expenses — TGTX leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is APLS or TGTX more undervalued right now?
Analyst consensus price targets imply the most upside for TGTX: 64.5% to $49.50.
07Which pays a better dividend — APLS or TGTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is APLS or TGTX better for a retirement portfolio?
For long-horizon retirement investors, TG Therapeutics, Inc. (TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43), +261.2% 10Y return). Both have compounded well over 10 years (TGTX: +261.2%, APLS: +49.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between APLS and TGTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.